Abstract library

1812 results for "patient stratification".
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Conference:
Category: Basic
Presenting Author: Dr Roberta Elisa Rossi
#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients
Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Andreas Kjær
Keywords: PET, PET/CT, imaging, survival
#54 The clinical challenge of patients with a thoracic or neck neuroendocrine tumor: a retrospective analysis from a single Irish institution
Introduction: Thoracic and neck neuroendocrine tumors (T-N-NETs) represent a rare and intriguing condition and the management of patients with a NET localized at the thorax or neck can be extremely problematic. An expert and multidisciplinary approach is generally required for the optimal management of NET patients. A systematic multidisciplinary approach to NET patients has been recently established at our institution.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Gianluca Tamagno
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone
#1397 The Relation Between GEP-NEN Prognosis Re-Stratification and Ki-67 Variability: From a Single Institution Study
Introduction: Ki-67 has been identified as a prognostic factor for GEP NEN.The variability of Ki-67 during the disease course has been reported,but there's few about its effects on prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Zhang Qin
Authors: Rong L, Qin Z, ...
#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education
Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P, ...
#1755 Immune-Related Factors Analysis Enhances the Stratification of GEP-NENs Patients Into Distinct Prognostic Subsets
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are divided into different prognostic categories according to Ki67 class (≤2%: 2%-20%; 20%-55%; >55%); treatment strategies based on this classification are not fully effective.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#1767 International Patient Survey of Physical, Emotional and Informational Challenges when Living with NETs: Understanding the Unmet Needs
Introduction: The usefulness of information sources used by NET patients is rarely explored by patient surveys of disease burden/impact on daily living, and may be key to optimizing care.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Khan M, Majdi A, Goldstein G, Mellar K, ...